The introduction of tirzepatide, the first dual agonist targeting both the GLP-1R and the glucose-dependent insulinotropic polypeptide (GIP) receptor, represents a new frontier in incretin-based therapy (Syed, 2022
Yes visceral fat and subcutaneous abdominal fat respond particularly well, consistent with how HGH's fat-metabolism effects work in the literature
A GLP-1 pill wouldnt need sophisticated cold-chain distribution and storage, meaning it could be sold in countries that dont have that infrastructure
While I thankfully have not seen any major negative outcomes with patients who have gone the route of compound drugs, it is a concern that this can lead to serious consequences if not properly dosed or prescribed, or due to the risk of contamination/sterility issues
Following is a list of the current FDA-approved GLP-1 agonists being prescribed for type 2 diabetes and/or weight loss
Copper tripeptide raised the Bcl-2/Bax ratio and reduced apoptosis markers in dermal papilla cells, biasing these cells toward survival rather than programmed death